4-phenoxypyridin-3-amine | 132038-28-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-phenoxypyridin-3-amine
• CAS: 132038-28-9
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD11184593
• 分子量: 186.213
• InChiKey: KJZZCHNYRGOHIP-UHFFFAOYSA-N

物化性质

• 沸点：
  138 °C(Press: 0.2 Torr)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-phenoxypyridin-3-amine 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 2-fluoro-N-[(2-methoxyphenyl)methyl]-N-(4-phenoxypyridin-3-yl)acetamide
  参考文献：
  名称：

  Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents

  摘要：

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.093
• 作为产物：
  描述：

  苯酚 在 10% Pd/C 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-phenoxypyridin-3-amine
  参考文献：
  名称：

  Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents

  摘要：

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.093
• 作为试剂：
  描述：

  4-phenoxypyridin-3-amine 、 2-acetoxybenzaldehyde 在 4-phenoxypyridin-3-amine 作用下， 以25的产率得到2-((4-苯氧基吡啶-3-基氨基)甲基)苯酚
  参考文献：
  名称：

  J. Med. Chem. 2008, 51, 17-30

  摘要：

  DOI：

文献信息

• [EN] GSK-3 INHIBITORS<br/>[FR] INHIBITEURS DE GSK-3
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015069594A1

  公开（公告）日：2015-05-14

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

  披露通常涉及到公式I的化合物，包括它们的盐，以及使用这些化合物治疗与GSK-3相关疾病的组合物和方法。
• Phenoxypyridinamine compounds which are use as a dermatological
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04959377A1

  公开（公告）日：1990-09-25

  There are described compounds of the formula ##STR1## where n is 0 or 1; X is hydrogen, loweralkyl, loweralkoxy, halogen, formyl, loweralkylcarbonyl, loweralkyoxycarbonyl, loweralkoxycarbonylloweralkyl or hydroxymethyl; Y is hydrogen or halogen;and R is hydrogen, loweralkyl arylloweralkyl or loweralkylcarbonyl, which compounds are useful as topical antiinflammatory agents for the treatment of various dermatoses.

  描述了一种化合物，其化学式为##STR1##其中n为0或1；X为氢、较低的烷基、较低的烷氧基、卤素、甲酰基、较低的烷基羰基、较低的烷氧羰基、较低的烷氧羰基较低的烷基或羟甲基；Y为氢或卤素；R为氢、较低的烷基芳基较低的烷基或较低的烷基羰基，这些化合物可用作治疗各种皮肤病的局部抗炎药。
• High colour rendering index and colour stable hybrid white efficient OLEDs with a double emitting layer structure using a single phosphorescence dopant of heteroleptic platinum complexes
  作者：Anurach Poloek、Chiao-Wen Lin、Chin-Ti Chen、Chao-Tsen Chen

  DOI：10.1039/c4tc01791a

  日期：——

  Voltage independent CIE and superb CRI of hybrid white OLEDs based on a platinum complex single dopant.

  基于铂配合物单掺杂剂的混合白色OLED具有电压独立的CIE和出色的CRI。
• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20140163000A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

  本发明涉及用作ATR蛋白激酶抑制剂的化合物。本发明还涉及包括本发明化合物的药学上可接受的组合物；使用本发明化合物治疗各种疾病、失调和病况的方法；制备本发明化合物的过程；制备本发明化合物的中间体；以及在体外应用中使用化合物的方法，例如研究生物和病理现象中的激酶、由这些激酶介导的细胞内信号转导途径的研究以及新激酶抑制剂的比较评估。本发明化合物具有式I：或药学上可接受的盐，其中变量如本文所定义。此外，本发明化合物具有式I-A：或药学上可接受的盐，其中变量如本文所定义。
• GSK-3 INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160272621A1

  公开（公告）日：2016-09-22

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

  本发明涉及公式I的化合物及其盐，以及使用这些化合物治疗与GSK-3相关的疾病的组合物和方法。